Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

XO1 Ltd.

Division of Johnson & Johnson

Latest From XO1 Ltd.

Medicxi Ventures Launches With €210 Million Fund

Index Ventures has spun off its life sciences team, portfolio companies and funds into a new venture capital firm called Medicxi Ventures, a validation of its "asset-centric" approach to investing.

BioPharmaceutical

J&J’s Top 10 List: Updates From Pharma Business Review

J&J presented a far-reaching overview of its pharmaceutical portfolio and pipeline at an analyst day May 20, including plans to break into immuno-oncology, a strategy to develop a pan-genotypic HCV regimen and several filing timelines for new drugs.

BioPharmaceutical Business Strategies

Deals Shaping The Medical Industry, April 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced March 2015.

BioPharmaceutical Medical Device

Deal Watch: Valeant Increases Bid, Wrests Salix Away From Endo

Janssen moves into a new generation of anticoagulation with X01 buyout. Lilly obtains Phase II-ready autoimmune candidate from South Korea’s Hanmi, which partnered a cancer compound with Spectrum just a week earlier, while AstraZeneca finds a commercialization partner for Movantik in Japan’s Daiichi Sankyo.

BioPharmaceutical Deals
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Johnson & Johnson
  • Senior Management
  • Richard Mason, CEO
    David J Grainger, PhD, CSO
    Robert W Schroff, PhD, COO
  • Contact Info
  • XO1 Ltd.
    Babraham Research Campus
    Cambridge, CB22 3AT
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register